Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Sahel coups push Africa to top of global democratic declines, report finds - 2Vote in favor of the bloom plan that adds a bit of excellence to your life!
- 3At least 36 dead in major fire in Hong Kong residential blocks
- 4Olivia Rodrigo announces 3rd album, 'You Seem Pretty Sad for a Girl So in Love,' set to debut in June
- 5In a scientific first, biologists recorded a wild wolf potentially using tools
- Addiction-stricken community struggles to keep a syringe program going after Trump's order
- Warnings rise for U.S. as severe flu strain causes outbreaks in Canada, U.K.
- How did this 20-light-year-wide 'Diamond Ring' form in space? Maybe a cosmic bubble burst
- Instructions to Pick the Ideal Pre-assembled Home for Your Necessities
- Why don’t humans have hair all over their bodies? A biologist explains our lack of fur
- ‘I love this work, but it’s killing me’: The unique toll of being a spiritual leader today
- Scientists find twisting magnetic waves on the sun. Could this help solve a huge solar mystery?
- Pick the Ideal Family Feline Variety for Your Home
- Most loved Public Dish: Which One Addresses Its Nation Best?
